The U.S. Food and Drug Administration has postponed the fast‑track review of Philip Morris International’s (PMI) nicotine‑pouch applications. The delay follows a scientific assessment of the potential for increased addiction among underage users and non‑tobacco users.
PMI’s nicotine pouches are a cornerstone of its smoke‑free growth strategy. In 2025, the company reported net revenues exceeding $40 billion, with smoke‑free products accounting for 41.5% of total net revenues. The U.S. nicotine‑pouch market is valued at approximately $22 billion, and PMI’s Zyn brand holds around two‑thirds of the value share.
Without the expedited clearance, the launch of PMI’s next‑generation nicotine‑pouch products could be delayed, potentially slowing the momentum that has driven the company’s recent growth. The postponement also creates an opening for competitors such as British American Tobacco and Turning Point Brands to capture additional market share.
Jacek Olczak, PMI’s CEO, said in February 2026, “2025 was another outstanding year for PMI. Our business is increasingly smoke‑free, with 27 markets exceeding the 50% net revenue milestone.” He added, “We achieved another remarkable year of results in 2025, with a fifth consecutive year of volume growth, net revenues surpassing $40 billion, including close to $17 billion from our smoke‑free business, and very good operating margin expansion.” Olczak also noted, “Another year of strong, profitable growth despite some transitory headwinds.”
Investors have viewed the FDA’s decision as a moderate negative catalyst, adding uncertainty to PMI’s projected revenue growth from its smoke‑free portfolio. The company’s 2026 outlook remains focused on organic net revenue growth of 5‑7% and organic operating income growth of 7‑9%, but the delay introduces a new variable into those forecasts.
The fast‑track pilot program, launched in September 2025, was intended to streamline the review of nicotine‑pouch products. PMI had previously received FDA authorization for 20 Zyn products in January 2025, and the current delay follows the agency’s ongoing evaluation of the next‑generation offerings.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.